PO64 COMPARISON OF FULVESTRANT VERSUS TAMOXIFEN FOR TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN

30% had multiple sites of metastasis. Most common site of metastasis was bone (50%) and brain (23%). All the patients of stage III-IV had received neoadjuvant chemotherapy for 3 cycles at least. 80% patients had received adjuvant chemotherapy according to the aggressiveness of the disease before/after loco regional RT. 68% patients also received adjuvant herceptin. With a median follow up of 6 months of treatment with lapatinib with capeciatbine, the overall response rate achieved was 75% with only 3 patients of solitary lung and liver metastasis showed complete response. 40% patients had partial response and 33% had stable disease and rest of the patients progressed. Bony symptoms were better controlled with palliative radiation and it was seen that pain control was much better in those patients who received this combination regimen. The time to progression ranged from 2 months to 6 months. All the patients tolerated well except 5 patients who presented with grade III diarrhea, responded with capecitabine dose reduction by 20%. Conclusion: It is well evident from this retrospective study that this combination regimen of lapatinib and capecitabine is effective and well tolerated in patients of HER2 +ve metastatic breast cancer. Further larger studies are required to confirm the significance of this combination regimen in our set up.